NCT04256941: Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study

NCT04256941
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: ESR1
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor, Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have received prior therapy for metastatic breast cancer (MBC)
Exclusions: Patients who have received prior therapy with fulvestrant in the metastatic setting; Patients with de novo metastatic disease
https://ClinicalTrials.gov/show/NCT04256941

Comments are closed.

Up ↑